A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT07703657 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

168

Enrollment

OTHER

Sponsor class

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation
Epstein-Barr Virus Reactivation
Clinically Significant EBV DNAemia

Interventions

DRUG: Rituximab (Arm A)
OTHER: Standard Post-Transplant Supportive Care

Sponsor

Yang Donglin